Ovation Science, Inc.

As of June 30, 2026, Ovation Science, Inc. carries a market capitalization of 576,625.22, placing it among publicly traded companies globally. Its enterprise value stands at 855,552.22, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Ovation Science, Inc. has 38.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 9.70, and the price-to-book ratio stands at -0.32.

These figures are as of June 30, 2026. The EV/Sales ratio of 14.92 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 855,552.22 versus a market cap of 576,625.22, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Ovation Science, Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -16.31, indicating conservative leverage, while an interest coverage ratio of -16.82 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -2,009.65, reflecting losses generated across the asset base.

As of the close on September 21, 2026, Ovation Science, Inc.'s stock has declined approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.04.

Over the twelve months ended June 30, 2026, Ovation Science, Inc. generated 57,344.00 in revenue and converted that into -655,911.00 in net income, yielding earnings per share of -0.02. EBITDA reached -613,724.00, while operating income came in at -613,724.00.

As of June 30, 2026, Ovation Science, Inc. holds 13,217.00 in cash and equivalents against 292,144.00 in total debt, resulting in a net debt position of 278,927.00. Total book value stands at -1.79M, with working capital of -1.79M providing operational flexibility.

Ovation Science, Inc. produced -138,125.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Ovation Science, Inc. posted a gross margin of 83.55, reflecting its pricing power and cost economics. The operating margin of -1,070.25 and net profit margin of -1,143.82 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -24.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow.

As of June 30, 2026, Ovation Science, Inc. has an Altman Z-Score of -593.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.